Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Iovance Biotherapeutics (IOVA) over the last 6 years, with Q3 2025 value amounting to $4.7 million.

  • Iovance Biotherapeutics' Gains from Sales and Divestitures rose 6167.69% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 6167.69%. This contributed to the annual value of $3.2 million for FY2024, which is 15131.71% up from last year.
  • Iovance Biotherapeutics' Gains from Sales and Divestitures amounted to $4.7 million in Q3 2025, which was up 6167.69% from $4.1 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Gains from Sales and Divestitures high stood at $4.7 million for Q3 2025, and its period low was $770257.0 during Q1 2023.
  • In the last 3 years, Iovance Biotherapeutics' Gains from Sales and Divestitures had a median value of $1.3 million in 2023 and averaged $2.2 million.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 1427.9% in 2024, then skyrocketed by 30427.84% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Gains from Sales and Divestitures (Quarter) stood at $1.3 million in 2023, then soared by 151.32% to $3.2 million in 2024, then surged by 47.66% to $4.7 million in 2025.
  • Its last three reported values are $4.7 million in Q3 2025, $4.1 million for Q2 2025, and $3.6 million during Q1 2025.